Molecular Docking Studies for Design, Synthesis and Characterization of New Imatinib Analogues

A. Hussein, O. Rasheed, M. F. Mahdi, Ayad M. R. Raauf
{"title":"Molecular Docking Studies for Design, Synthesis and Characterization of New Imatinib Analogues","authors":"A. Hussein, O. Rasheed, M. F. Mahdi, Ayad M. R. Raauf","doi":"10.35248/2153-2435.19.10.616","DOIUrl":null,"url":null,"abstract":"Background: In silico drug design conducts a process for making conformations and directions of multiple ligands and chooses the best ones, then being selected. In silico studies are used to examine and model molecular interactions between target macromolecules and ligand. Tyrosine kinase is considered a potential target to design inhibitors. Tyrosine kinase inhibitor like imatinib this drug has succeeded to pass through clinical studies in an attempt to cure the cancer, which is considered as the second leading cause of deaths in the world. In this work, the GOLD program was employed to predict the bindings and thus the inhibitory activity toward the tyrosine kinase. Methodology: After the design and docking processes, the chemical synthesis of three imatinib analogues was achieved. Results: the percent of yield of the chemical synthesis was (81-85%). The synthesized compounds were well characterized using FTIR, NMR, DSC, and CHN elemental analyser. The present purity was within the globally accepted value of less than 0.4% with the employment of CHN combustion.","PeriodicalId":19833,"journal":{"name":"Pharmaceutica Analytica Acta","volume":"146 1","pages":"1-9"},"PeriodicalIF":0.0000,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceutica Analytica Acta","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.35248/2153-2435.19.10.616","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 4

Abstract

Background: In silico drug design conducts a process for making conformations and directions of multiple ligands and chooses the best ones, then being selected. In silico studies are used to examine and model molecular interactions between target macromolecules and ligand. Tyrosine kinase is considered a potential target to design inhibitors. Tyrosine kinase inhibitor like imatinib this drug has succeeded to pass through clinical studies in an attempt to cure the cancer, which is considered as the second leading cause of deaths in the world. In this work, the GOLD program was employed to predict the bindings and thus the inhibitory activity toward the tyrosine kinase. Methodology: After the design and docking processes, the chemical synthesis of three imatinib analogues was achieved. Results: the percent of yield of the chemical synthesis was (81-85%). The synthesized compounds were well characterized using FTIR, NMR, DSC, and CHN elemental analyser. The present purity was within the globally accepted value of less than 0.4% with the employment of CHN combustion.
新型伊马替尼类似物设计、合成与表征的分子对接研究
背景:硅药物设计是对多个配体的构象和方向进行确定,并从中选择最佳配体,然后进行筛选的过程。在硅研究被用来检查和模拟分子之间的相互作用目标大分子和配体。酪氨酸激酶被认为是设计抑制剂的潜在靶点。像伊马替尼这样的酪氨酸激酶抑制剂已经成功地通过了临床研究,试图治愈被认为是世界上第二大死亡原因的癌症。在这项工作中,黄金程序被用来预测结合,从而对酪氨酸激酶的抑制活性。方法:经过设计和对接过程,实现了三种伊马替尼类似物的化学合成。结果:化学合成收率为(81 ~ 85%)。用FTIR、NMR、DSC和CHN元素分析仪对合成的化合物进行了表征。采用CHN燃烧,目前的纯度在全球公认的0.4%以内。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信